Assessment of serum levels of monocyte chemoattractant protein 1 (MCP 1) in patients with periodontitis and atherosclerotic cardiovascular disease
Main Article Content
Abstract
Background: Monocyte chemotactic protein-1 (MCP-1) is a chemokine expressed by inflammatory and endothelial cells. It has a crucial role in initiating, regulating, and mobilizing monocytes to active sites of periodontal inflammation. Its expression is also elevated in response to pro-inflammatory stimuli and tissue injury, both of which are linked to atherosclerotic lesions. Aim of the study: To determine the serum level of MCP-1 in patients with periodontitis and atherosclerotic cardiovascular disease in comparison to healthy control and evaluate the biomarker's correlations with periodontal parameters. methods: This study enrolled 88 subjects, both males and females, ranging in age from 36-66 years old, and divided into four groups: 1ST group with atherosclerotic cardiovascular disease (ASCVD) without periodontal disease (25 patients), 2nd group with periodontitis and systemically healthy, (25 patients),3rdgroup having both ASCVD and periodontitis (25 patients), and the 4th is the control group without any systemic disease and with good oral hygiene (13 subjects). The clinical periodontal parameters plaque index (PL I), Bleeding on probing (BOP), Probing Pocket depth (PPD) and clinical attachment level (CAL) were used to evaluate periodontal health status. Atherosclerotic cardiovascular disease patients were chosen after clinical examination by specialists and diagnoses confirmed with catheterization. Following clinical assessment, 5ml of venous blood was drawn from each participant MCP-1 levels in the blood were then measured using enzyme-linked-immunosorbent assay (ELISA). Results: According to the findings of this study, the mean values of PLI and BOP were higher in periodontitis group and athero+periodontitis group than in athero group and control group, PPD and CAL mean values were greater in athero+periodontitis group than in periodontitis group. The serum level of MCP-1 was higher in athero+periodontitis group than in athero, periodontitis and control groups. Regarding the correlations between MCP-1 and clinical periodontal parameters. In periodontitis group there was a positive correlation with PPD and CAL and there was a positive correlation with CAL in athero+periodontitis. Conclusion: This study revealed that periodontitis with higher MCP-1 level may be linked to an increased risk of atherosclerosis.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Peres MA, Macpherson LM, Weyant RJ, Daly B, Venturelli R, Mathur MR, et al. Oral diseases: Glob. Public Health. The Lancet. 2019;394(10194):249-60.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
Zardawi F, Gul S, Abdulkareem A, Sha A, Yates J. Association between periodontal disease and atherosclerotic cardiovascular diseases: revisited. FRONT CARDIOVASC MED . 2020;7.
Peacock ME, Carson RE. Frequency of self‐reported medical conditions in periodontal patients. J. Periodontol. 1995;66(11):1004-7.
Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. Jama. 2000;284(11):1406-10.
Reyes L, Herrera D, Kozarov E, Roldán S, Progulske‐Fox A. Periodontal bacterial invasion and infection: contribution to atherosclerotic pathology. J. Clin. Periodontol. 2013;40:S30-S50.
Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J. Periodontol. 2013;84:S51-S69.
Tonetti MS, Van Dyke TE, workshop* wgotjEA. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAPWorkshop on Periodontitis and Systemic Diseases. J. Periodontol. 2013;84:S24-S9.
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009;29(6):313-26.
Conti I, Rollins BJ, editors. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol; 2004: Elsevier.
Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 2011;107(6):906-11.
Silva T, Garlet G, Fukada S, Silva J, Cunha F. Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J. Dent. Res. 2007;86(4):306-19.
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J. Periodontol. 2018;89:S159-S72.
Chapple IL, Mealey BL, Van Dyke TE, Bartold PM, Dommisch H, Eickholz P, et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri‐Implant Diseases and Conditions. J. Periodontol. 2018;89:S74-S84.
O'Leary TJ, Drake RB, Naylor JE. The plaque control record. J. Periodontol. 1972;43(1):38-.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155-63.
Buhlin K, Mäntylä P, Paju S, Peltola JS, Nieminen MS, Sinisalo J, et al. Periodontitis is associated with angiographically verified coronary artery disease. J. Clin. Periodontol. 2011;38(11):1007-14.
López‐Jornet P, Berná‐Mestre J, Berná‐Serna J, Camacho‐Alonso F, Fernandez‐Millan S, Reus‐Pintado M. Measurement of atherosclerosis markers in patients with periodontitis: A case‐control study. J. Periodontol. 2012;83(6):690-8.
Vražić D, Miovski Z, Strozzi M, Puhar I, Badovinac A, Božić D, et al. Periodontal disease and its association with angiographically verified coronary artery disease. Acta Stomatol Croat. 2015;49(1):14-20.
Androsz-Kowalska O, Jankowski K, Rymarczyk Z, Kowalski J, Pruszczyk P, Górska R. Correlation between clinical parameters of periodontal disease and mean platelet volume in patients with coronary artery disease: a pilot study. Kardiol Pol. 2013;71(6):600-5.
Zhu H, Lin X, Zheng P, Chen H. Inflammatory cytokine levels in patients with periodontitis and/or coronary heart disease. Int J Clin Exp Pathol. 2015;8(2):2214.
Lira‐Junior R, Figueredo CM, Bouskela E, Fischer RG. Severe chronic periodontitis is associated with endothelial and microvascular dysfunctions: a pilot study. J. Periodontol. 2014;85(12):1648-57.
Bartova J, Sommerova P, Lyuya-Mi Y, Mysak J, Prochazkova J, Duskova J, et al. Periodontitis as a risk factor of atherosclerosis. J. Immunol. Res. 2014;2014.
Baker PJ. The role of immune responses in bone loss during periodontal disease. Microbes Infect. 2000;2(10):1181-92.
Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R. IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract . 2000;48(2):127-38.
Dwivedi A, Änggård EE, Carrier MJ. Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve NFκB. Biochem. Biophys. Res. Commun. 2001;284(1):239-44.
Pradeep A, Daisy H, Hadge P. Serum levels of monocyte chemoattractant protein-1 in periodontal health and disease. Cytokine. 2009;47(2):77-81.
Gupta M, Chaturvedi R, Jain A. Role of monocyte chemoattractant protein-1 (MCP-1) as an immune-diagnostic biomarker in the pathogenesis of chronic periodontal disease. Cytokine. 2013;61(3):892-7.
Babu DS, Poornodaya S, Sai KA, Anumala D, Reddy DS, Reddy NR. Estimation of CCL2/MCP-1 levels in serum and gingival crevicular fluid in periodontal health, disease and after treatment–A clinico biochemical study. J. Orofac. Sci. 2017;9(2):85.
Kinane DF, Lappin DF. Clinical, pathological and immunological aspects of periodontal disease. Acta Odontol. Scand. 2001;59(3):154-60.
Graves DT, Cochran D. The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. J. Periodontol. 2003;74(3):391-401.
Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFκB ligand for bone resorption. J. Biol. Chem. 2006;281(2):1274-85.
Kim MS, Magno CL, Day CJ, Morrison NA. Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP‐1 and RANTES. J. Cell. Biochem. 2006;97(3):512-8.